{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:31:46Z","timestamp":1791498706625,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,12,7]],"date-time":"2010-12-07T00:00:00Z","timestamp":1291680000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1038\/leu.2010.226","type":"journal-article","created":{"date-parts":[[2010,12,7]],"date-time":"2010-12-07T09:41:40Z","timestamp":1291714900000},"page":"341-347","source":"Crossref","is-referenced-by-count":262,"title":["A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma"],"prefix":"10.1038","volume":"25","author":[{"given":"T E","family":"Witzig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C B","family":"Reeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B R","family":"LaPlant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P B","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I N","family":"Micallef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L F","family":"Porrata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S M","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J P","family":"Colgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E D","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I M","family":"Ghobrial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T M","family":"Habermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,12,7]]},"reference":[{"key":"BFleu2010226_CR1","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","volume":"24","author":"TM Habermann","year":"2006","unstructured":"Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 3121\u20133127.","journal-title":"J Clin Oncol"},{"key":"BFleu2010226_CR2","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","volume":"112","author":"CH Geisler","year":"2008","unstructured":"Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008; 112: 2687\u20132693.","journal-title":"Blood"},{"key":"BFleu2010226_CR3","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/cncr.23537","volume":"113","author":"DJ Inwards","year":"2008","unstructured":"Inwards DJ, Fishkin PA, Hillman DW, Brown DW, Ansell SM, Kurtin PJ et al. Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. Cancer 2008; 113: 108\u2013116.","journal-title":"Cancer"},{"key":"BFleu2010226_CR4","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1200\/JCO.2008.16.0283","volume":"26","author":"AJ Al-Tourah","year":"2008","unstructured":"Al-Tourah AJ, Gill KK, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 5165\u20135169.","journal-title":"J Clin Oncol"},{"key":"BFleu2010226_CR5","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s11864-006-0038-1","volume":"7","author":"TE Witzig","year":"2006","unstructured":"Witzig TE, Kaufmann SH . Inhibition of the phosphatidylinositol 3-kinase\/mammalian target of rapamycin pathway in hematologic malignancies. Curr Treat Options Oncol 2006; 7: 285\u2013294.","journal-title":"Curr Treat Options Oncol"},{"key":"BFleu2010226_CR6","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nrc1819","volume":"6","author":"M Cully","year":"2006","unstructured":"Cully M, You H, Levine AJ, Mak TW . Beyond PTEN mutations: the PI3\u2009K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006; 6: 184\u2013192.","journal-title":"Nat Rev Cancer"},{"key":"BFleu2010226_CR7","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.drup.2007.11.003","volume":"11","author":"J LoPiccolo","year":"2008","unstructured":"LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA . Targeting the PI3K\/Akt\/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 2008; 11: 32\u201350.","journal-title":"Drug Resist Updat"},{"key":"BFleu2010226_CR8","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.bbapap.2009.12.001","volume":"1804","author":"RJ Dowling","year":"2010","unstructured":"Dowling RJ, Topisirovic I, Fonseca BD, Sonenberg N . Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim Biophys Acta 2010; 1804: 433\u2013439.","journal-title":"Biochim Biophys Acta"},{"key":"BFleu2010226_CR9","doi-asserted-by":"publisher","first-page":"727","DOI":"10.7164\/antibiotics.28.727","volume":"28","author":"SN Sehgal","year":"1975","unstructured":"Sehgal SN, Baker H, Vezina C . Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo) 1975; 28: 727\u2013732.","journal-title":"J Antibiot (Tokyo)"},{"key":"BFleu2010226_CR10","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271\u20132281.","journal-title":"N Engl J Med"},{"key":"BFleu2010226_CR11","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449\u2013456.","journal-title":"Lancet"},{"key":"BFleu2010226_CR12","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1182\/blood-2009-05-220889","volume":"114","author":"M Gupta","year":"2009","unstructured":"Gupta M, Ansell SM, Novak AJ, Kumar S, Kaufmann SH, Witzig TE . Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood 2009; 114: 2926\u20132935.","journal-title":"Blood"},{"key":"BFleu2010226_CR13","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","volume":"23","author":"TE Witzig","year":"2005","unstructured":"Witzig TE, Geyer SM, Ghobrial I, Inwards DJ, Fonseca R, Kurtin P et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23: 5347\u20135356.","journal-title":"J Clin Oncol"},{"key":"BFleu2010226_CR14","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/cncr.23580","volume":"113","author":"SM Ansell","year":"2008","unstructured":"Ansell SM, Inwards DJ, Rowland Jr KM, Flynn PJ, Morton RF, Moore Jr DF et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer 2008; 113: 508\u2013514.","journal-title":"Cancer"},{"key":"BFleu2010226_CR15","doi-asserted-by":"publisher","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","volume":"27","author":"G Hess","year":"2009","unstructured":"Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27: 3822\u20133829.","journal-title":"J Clin Oncol"},{"key":"BFleu2010226_CR16","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1158\/1078-0432.CCR-06-0764","volume":"12","author":"KW Yee","year":"2006","unstructured":"Yee KW, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A et al. Phase I\/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2006; 12: 5165\u20135173.","journal-title":"Clin Cancer Res"},{"key":"BFleu2010226_CR17","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1200\/JCO.2009.24.0994","volume":"28","author":"IM Ghobrial","year":"2010","unstructured":"Ghobrial IM, Gertz M, Laplant B, Camoriano J, Hayman S, Lacy M et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010; 28: 1408\u20131414.","journal-title":"J Clin Oncol"},{"key":"BFleu2010226_CR18","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1002\/cncr.25005","volume":"116","author":"CS Zent","year":"2010","unstructured":"Zent CS, LaPlant BR, Johnston PB, Call TG, Habermann TM, Micallef IN et al. The treatment of recurrent\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. Cancer 2010; 116: 2201\u20132207.","journal-title":"Cancer"},{"key":"BFleu2010226_CR19","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/ajh.21664","volume":"85","author":"PB Johnston","year":"2010","unstructured":"Johnston PB, Inwards DJ, Colgan JP, Laplant BR, Kabat BF, Habermann TM et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010; 85: 320\u2013324.","journal-title":"Am J Hematol"},{"key":"BFleu2010226_CR20","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"B Cheson","year":"1999","unstructured":"Cheson B, Horning S, Coiffier B, Shipp M, Fisher R, Connors J et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 1244\u20131253.","journal-title":"J Clin Oncol"},{"key":"BFleu2010226_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R . Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1\u201310.","journal-title":"Control Clin Trials"},{"key":"BFleu2010226_CR22","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"E Kaplan","year":"1958","unstructured":"Kaplan E, Meier P . Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958; 53: 457\u2013481.","journal-title":"J Am Stat Assoc"},{"key":"BFleu2010226_CR23","doi-asserted-by":"publisher","first-page":"7800","DOI":"10.1158\/0008-5472.CAN-04-4180","volume":"65","author":"P Wlodarski","year":"2005","unstructured":"Wlodarski P, Kasprzycka M, Liu X, Marzec M, Robertson ES, Slupianek A et al. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase\/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum. Cancer Res 2005; 65: 7800\u20137808.","journal-title":"Cancer Res"},{"key":"BFleu2010226_CR24","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/path.1725","volume":"205","author":"A Dutton","year":"2005","unstructured":"Dutton A, Reynolds GM, Dawson CW, Young LS, Murray PG . Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR. J Pathol 2005; 205: 498\u2013506.","journal-title":"J Pathol"},{"key":"BFleu2010226_CR25","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/sj.leu.2404471","volume":"21","author":"T Haritunians","year":"2007","unstructured":"Haritunians T, Mori A, O\u2019Kelly J, Luong QT, Giles FJ, Koeffler HP . Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 2007; 21: 333\u2013339.","journal-title":"Leukemia"},{"key":"BFleu2010226_CR26","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1365-2141.2006.06210.x","volume":"134","author":"K Wanner","year":"2006","unstructured":"Wanner K, Hipp S, Oelsner M, Ringshausen I, Bogner C, Peschel C et al. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. Br J Haematol 2006; 134: 475\u2013484.","journal-title":"Br J Haematol"},{"key":"BFleu2010226_CR27","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","volume":"26","author":"PH Wiernik","year":"2008","unstructured":"Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 4952\u20134957.","journal-title":"J Clin Oncol"},{"key":"BFleu2010226_CR28","doi-asserted-by":"publisher","first-page":"4536","DOI":"10.1200\/JCO.2008.21.3033","volume":"27","author":"SL Ellard","year":"2009","unstructured":"Ellard SL, Clemons M, Gelmon KA, Norris B, Kennecke H, Chia S et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent\/metastatic breast cancer: NCIC Clinical Trials Group IND163. J Clin Oncol 2009; 27: 4536\u20134541.","journal-title":"J Clin Oncol"},{"key":"BFleu2010226_CR29","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1200\/JCO.2009.24.2669","volume":"28","author":"JC Yao","year":"2010","unstructured":"Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010; 28: 69\u201376.","journal-title":"J Clin Oncol"},{"key":"BFleu2010226_CR30","doi-asserted-by":"publisher","first-page":"5767","DOI":"10.1200\/JCO.2008.17.7279","volume":"26","author":"P Armand","year":"2008","unstructured":"Armand P, Gannamaneni S, Kim HT, Cutler CS, Ho VT, Koreth J et al. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol 2008; 26: 5767\u20135774.","journal-title":"J Clin Oncol"},{"key":"BFleu2010226_CR31","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1038\/onc.2009.403","volume":"29","author":"V Ramakrishnan","year":"2010","unstructured":"Ramakrishnan V, Timm M, Haug JL, Kimlinger TK, Wellik LE, Witzig TE et al. Sorafenib, a dual Raf kinase\/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. Oncogene 2010; 29: 1190\u20131202.","journal-title":"Oncogene"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu2010226.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2010226","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2010226.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T20:57:40Z","timestamp":1712005060000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2010226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,7]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["BFleu2010226"],"URL":"https:\/\/doi.org\/10.1038\/leu.2010.226","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,7]]}}}